Wolfgang Miesbach: How SUMOylation Limits AAV Gene Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”Gene therapy: same vector, same dose — up to 20 times more transgene.
Vector delivers the gene — the hepatocyte determines how efficiently it works.
At ISTH 2026, Denise Sabatino presented data identifying SUMOylation — a common host post-translational modification — as a restriction factor for transgene expression in AAV-transduced cells.
The agent: TAK-981 (subasumstat), a clinical-stage SUMO-activating enzyme inhibitor.
- In vitro: up to approximately 20 times higher transgene expression, across all cell types and promoters tested
- In vivo: around 36 times, 90 times and 200 times luciferase at days 1, 2 and 3
- Vector copy number lower while transgene mRNA and protein higher — driven not by increased vector uptake but by de-repression within the transduced cell
- Therapeutic transgenes: around 4 times FVIII (haemophilia A) and ~2× FIX-Padua (haemophilia B), including dosing months after transduction
- Effect transient and repeatable — a pharmacologically tunable intervention
SUMO-mediated restriction is an underappreciated limitation of AAV gene therapy, independent of serotype, promoter and transgene.
Modulating it may improve the durability and efficacy of expression — a relevant target for a field focused on long-term, predictable transgene output.”
Stay updated with Hemostasis Today.
-
Jul 22, 2026, 16:46Congressman Don Davis: Working Toward a Better Future for Rare Disease Patients
-
Jul 22, 2026, 15:27Obstetric APS: From Standardized Anticoagulation to Biology-Driven Precision Care
-
Jul 22, 2026, 14:31What Could Shape the Future of Hemophilia A Care? – Novo Nordisk Medical US
-
Jul 22, 2026, 10:35Ifeanyichukwu Ifechidere: We’ve Trained an Entire Generation of Clinicians to Fear The Wrong Thing About HIT
-
Jul 22, 2026, 10:16Ney Carter Borges: Understanding Pathophysiology as the Foundation of Precision Cardiovascular Care
-
Jul 22, 2026, 10:01George Cieutat: Strengthening Connections Across the Bleeding Disorders Community
-
Jul 22, 2026, 09:57Ming Y Lim: Demonstrating the Value of Upfront Emicizumab at ISTH 2026
-
Jul 22, 2026, 09:52Danny Hsu: Get to Do Some Fun Stuff at ISTH 2026
-
Jul 22, 2026, 09:48Nita Radhakrishnan: The People Behind the Science at ISTH 2026